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Abstract
Over the next few years, the efficient use of next-generation sequencing (NGS) in human genetics research will depend
heavily upon the effective mechanisms for the selective enrichment of genomic regions of interest. Recently,
comprehensive exome capture arrays have become available for targeting approximately 33 Mb or ,180,000 coding
exons across the human genome. Selective genomic enrichment of the human exome offers an attractive option for new
experimental designs aiming to quickly identify potential disease-associated genetic variants, especially in family-based
studies. We have evaluated a 2.1 M feature human exome capture array on eight individuals from a three-generation family
pedigree. We were able to cover up to 98% of the targeted bases at a long-read sequence read depth of $3, 86% at a read
depth of $10, and over 50% of all targets were covered with $20 reads. We identified up to 14,284 SNPs and small indels
per individual exome, with up to 1,679 of these representing putative novel polymorphisms. Applying the conservative
genotype calling approach HCDiff, the average rate of detection of a variant allele based on Illumina 1 M BeadChips
genotypes was 95.2% at $10x sequence. Further, we propose an advantageous genotype calling strategy for low covered
targets that empirically determines cut-off thresholds at a given coverage depth based on existing genotype data.
Application of this method was able to detect .99% of SNPs covered $8x. Our results offer guidance for ‘‘real-world’’
applications in human genetics and provide further evidence that microarray-based exome capture is an efficient and
reliable method to enrich for chromosomal regions of interest in next-generation sequencing experiments.
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Introduction
Despite the continued increases in next-generation sequencing
(NGS) platform throughput, the cost of obtaining and analyzing
full genome sequences on a large number of human individuals
remains prohibitive. Therefore, at least for the near future, large
scale human genetic studies will rely on techniques that select and
enrich for chromosomal regions of interest prior to sequencing.
This approach will allow for the efficient evaluation of the
hundreds of individual samples typically required to detect risk-
associated genetic variation in common complex disorders. In
addition to the adaptation of PCR and microfluidics-based
techniques to select genomic regions of interest [1,2], new versions
of array-based and solution-based hybridization methods provide
promising genomic enrichment approaches [3–9]. Recently,
Roche Nimblegen has made available a microarray-based
sequence capture system that targets the majority of coding exons
as listed in the Consensus Coding Sequences (CCDS) collection.
This human exome capture array covers 33 Mb of genomic
sequence, comprising ,180,000 exons and over 500 miRNA
genes. Since captured DNA fragments have an average size of
500 bp, NGS sequence reads frequently extend beyond targeted
coding exons into the intron/exon boundary.
Although sequence variants in non-coding regulatory loci
clearly have potential to result in pathology, Mendelian disease
studies suggest that a large portion of disease-associated variation
lies within coding exons [10,11]. Recent studies seeking to identify
clusters of rare variants related to complex phenotypes have also
focused on coding exons [12–15], in part because available in silico
tools allow for rapid assessment of the potential functional
consequences of any novel variants.
While the sequences of five exomes have been examined in the
context of full human genome sequences [16–20], to date 13
exome-scale sequences derived from capture methods followed by
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smaller-scale studies, [6,22] have carefully examined the efficiency,
reproducibility, and uniformity of targeted genomic capture/
enrichment using array-based methodologies, as well as the extent
to which allelic bias and GC-content influence results.
Here, we present the results from eight complete exomes
captured via 2.1 M feature capture arrays (Roche). NGS was
carried out on the 454 Genome Sequencer FLX (GS FLX)
platform (Roche). Eight individuals were selected from a three
generation pedigree. This approach allowed for cross-validation of
segregating variants and facilitated genotype evaluation. The
samples used in this study were extracted from peripheral blood,
and DNA was stored for 13 years, representing conditions that are
not uncommon for larger human genetic disease sample
collections. We outline an empirical optimization approach to
genotype calling in individual exomes, assess the reliability of
genotype calling, and provide an overall evaluation of array-based
exome capture followed by NGS analysis on the 454 platform.
Methods
Human Subjects and DNA Samples
We examined eight individuals from a three generation family
pedigree (Fig. 1). All family members are of self-reported
European descent. Written informed consent for genetic studies
was obtained prior to initiating this study in agreement with
protocols approved by the institutional review board (IRB) at the
University of Miami Miller School of Medicine. DNA was
extracted from peripheral blood leukocytes using automated
DNA extraction. DNA samples were stored for approximately
13 years at the Biorepository of the John P. Hussman Institute for
Human Genomics, University of Miami. Before usage in this
study, DNA aliquots were re-precipitated and treated with RNAse
to remove proteins and RNA remnants (Fig. S1).
Exome Capture
Exome capture was performed using 5 ug of input DNA
according to the manufacturer’s protocol (Roche Nimblegen).
Briefly, genomic DNA was nebulized for 1 minute using 45psi of
pressure. Sheared DNA fragments were subsequently cleaned with
the DNA Clean & Concentrator-25 Kit (Zymo Research) and a
fragment size distribution ranging from 300 bp to 500 bp was
verified via Bioanalyzer (Agilent). After end-polishing of the
genomic fragments, the GS FLX Titanium adaptors were ligated
to the sheared genomic fragments. Ligated fragments were next
hybridized to the 2.1 M exome array within Maui hybridization
stations, followed by washing and elution of array-bound
fragmentsfrom the arrays within elution chambers (Nimblegen).
Captured fragments were next subjected to 27 rounds of PCR
amplification using primers targeting the Nimblegen linkers.
Following elution, the capture efficiency was evaluated via q-
PCR reactions. For additional details, see manufacturer’s protocol
that was modified for the human exome arrays (http://www.
nimblegen.com/products/lit/SeqCap_UserGuide_Tit_Del_v1p0.
pdf).
Next-Generation Sequencing
Captured DNA samples were subjected to standard sample
preparation procedures for 454 GS FLX sequencing as recom-
mended by the manufacturer (Roche Inc.). Two full 454 GS FLX
(Titanium) runs were performed for each of the eight samples with
the exception of individual 10039, which was sequenced using a
total of four full 454 GS FLX runs.
Array-Based Genotyping
We processed all individuals on the Illumina 1 M Duo
BeadChip, following the manufacturer’s recommendations (Illu-
mina Inc.). BeadChip arrays were scanned on the iScan
instrument, and preliminary analysis was conducted using
Illumina BeadStudio v3.29 software. Quality-control tests for
genotyping calls included the following measures: samples were
required to have an overall genotype call efficiency of $0.98;
Mendelian inconsistency checks were performed using WASP
[23]; reported gender and genetically determined gender were
examined with the use of X-linked SNPs, and we required a
conservative gencall score of 0.25. Variant loci with more than
10% missing genotypes and SNPs with minor allele frequency
,1% across all individuals were dropped from the analysis. To
determine high quality SNPs we applied the PLINK software [24].
Capillary Sequencing
For follow-up confirmation of identified novel variants we also
applied capillary sequencing. PCR primers were designed flanking
approximately 200 bp of a given variant and sequenced on an ABI
3730 capillary sequencing instrument following standard proce-
dures (Life Technologies). Capillary sequence reads were analyzed
using the Sequencher software package (GeneCodes Inc.).
Bioinformatics and Statistical Analyses
Next-generation sequencing data were initiallyprocessedusing
the GSMapper software package (Roche Inc.) supplied with the
GS FLX instrument. High quality sequencing reads were aligned
to the human genome reference sequence NCBI 36.1. Variants
with respect to NCBI 36.1 reference sequence were identified
with the GSMapper software (AllDiff and HCDiff reports). The
A l l D i f f( a l ld i f f e r e n c e s )s t r a t e g y (output in the GSMapper AllDiff
file) requires the following criteria for a variant to be reported: (1)
At least two reads differ either from the reference sequence or
Figure 1. Studied three-generational pedigree. Pedigree of eight
individuals of European descent that was studied with exome capture
arrays.
doi:10.1371/journal.pone.0008232.g001
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least two non-duplicate reads that a) show the difference, b) have
a tl e a s t5b a s e so nb o t hs i d e so ft h ed i f f e r e n c e ,a n dc )h a v ef e w
other isolated sequence differences in the read. HCDiff (high
confidence differences) requires the following criteria for a
v a r i a n tt ob er e p o r t e d :1 )T h e r em u s tb ea tl e a s t3r e a d sw i t ht h e
difference.; 2) There must be both forward and reverse reads
showing the difference, unless there are at least 5 reads with
quality scores over 20 (or 30 if the difference involves a 5-mer or
higher).; 3) If the difference is a single-base overcall or undercall,
t h e nt h er e a d sw i t ht h ed i f f e r e n c em u s tf o r mt h ec o n s e n s u so ft h e
sequenced reads. Coverage depth at all detected variants and at
all positions corresponding to an Illumina 1 M genotype were
extracted for the purpose of comparison with the output files
H C D i f fa n dA l l D i f fg e n e r a t e db yt h eR o c h eG e n e M a p p e r
software.
Empirical Optimization of Genotype Calling
To determine empirical allele frequency threshold values for
assigning sequence-derived genotypes in our study, we obtained
genotype data for each individual in our study from a set of
44,513 Illumina 1 M Duo SNPs that fell within our targeted
exonic regions. The data set was arbitrarily divided into two
approximately equal SNP sets. We used the first set as a training
set to establish calling thresholds, and the second set was used for
the validation of the calling strategy. We defined lower (cl) and
upper (cu) thresholds such that if the percent of non-reference
reads is less than cl, then the genotype is called homozygous for
the reference allele; if the percent of non-reference reads was
between cl and cu the genotype is called heterozygous; and if the
percent of variant reads wasgreater than cuthe genotype is called
homozygous for the non-reference allele. For each given depth of
coverage, we determined the threshold values for assigning
genotypes (based on the frequency of non-reference alleles
present among the set of sequence fragments) such that the
genotyping calls yielded the highest percent identity with the
Illumina training data set. Due to the nature of NGS data, more
training data were available for some call depths than others. We
required a minimum of 50 genotypes be present in the training
set to set a threshold at a given coverage depth. Using these
criteria, we established calling thresholds for the range of 3X to
23X coverage.
Results and Discussion
Exome Capture
Prior to exome capture, all DNA samples underwent quality
controls, including agarose gel runs and spectrophotometric
quantification (Fig. S1). The capture/enrichment of targeted
exons using the human exome array was carried out following the
manufacturer’s recommendations (see Methods). Successful en-
richment was initially evaluated by four real-time qPCR control
targets present on the array. After elution of the sequence capture
reactions, an estimated enrichment of control targets ranging from
53 to 102-fold over background was measured based on qPCR
data (Table S1).
NGS Run Statistics
For each of eight individuals we obtained between 0.7 and
1.3 Gb of genomic sequence from two GS FLX runs. One subject
(10039) was sequenced with a total of four GS FLX runs, resulting
in ,2 Gb of data. The average read length obtained was 340 bp
(Table 1). Fragment sizes ranged from 50 bp (the minimal length
used for analysis) to a maximum of 835 bp. All sequencing runs
yielded comparable average sequence lengths and total sequence
amounts. Run statistics for each sample are given in Table 1.
Target Coverage
Initial analysis of the NGS sequence results was conducted using
the GSMapper software package, which is optimized for the long
read alignment produced by the GS FLX platform. By applying
default GSMapper settings, which exclude low quality reads from
alignment, .99% of all remaining sequence fragments mapped to
the human genome reference NCBI36.1 (Table 1). Between
71.6% and 82.9% of all reads from each individual fell within a
region targeted by the human exome array, yielding an average
capture efficiency of 77.9% (Table 1). For comparison, we would
expect ,2% of reads to uniquely map to targeted regions were no
enrichment strategy employed. Our capture efficiencies resulted in
91% to 94% of all targeted bases being covered by at least three
sequence reads (Fig. 2). On average, two full 454 FLX runs (or
,1 Gb of sequence) resulted in ,50% of all targets being covered
by ten or more reads and ,30% of all targets covered by a depth
of greater than 15x (Fig. 2). The average coverage over all
individuals was 8.82. In individual (10039), with 2 Gb of sequence
Table 1. NGS run statistics for eight exomes aligning high-quality sequencing reads.
Individual
mapped bases (bp)/ %
of total bases
# mapped unique
reads
1/ % of total reads
Unique reads
1in target
region/ % of all reads
Target Base
Coverage
Average read
length (bp)
Max read
length * (bp)
10032 926,438,032 (99.79%) 2459464 (99.35%) 1854613 (78.02%) 92.50% 369 677
10033 814,175,547 (99.73%) 2275083 (99.26%) 1570217 (71.60%) 91.20% 345 635
10034 750,594,870 (99.76%) 2169892 (99.33%) 1532537 (73.18%) 90.90% 335 732
10035 1,146,776,462 (99.69%) 3293074 (99.28%) 2457890 (77.45%) 93.60% 339 755
10036 1,333,018,529 (99.71%) 3995447 (99.21%) 3099809 (80.26%) 93.20% 328 728
10037 892,370,696 (99.75%) 2421459 (99.30%) 1875210 (80.15%) 92.80% 360 736
10039 912,259,209 (99.78%) 2583714 (99.29%) 1984028 (79.68%) 94.20% 347 755
10082 670,270,644 (99.63%) 2197618 (98.80%) 1753660 (82.92%) 92.20% 299 835
Average 930,737,999(99.73%) 2,674,468 (99.23%) 2,015,995 (77.91%) 92.58% 340 732
#Number of.
*The minimum read length required was 50 bp.
1Before alignment, all raw reads were screened for duplicate reads, which are introduced by amplification steps during library preparation on next-generation platforms.
Only the first two runs are shown for better comparison.
doi:10.1371/journal.pone.0008232.t001
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targets were covered at $10X, and ,70% of targets were covered
$15x (Fig. 2).
Variant Detection and Genotype Designation
Variant detection was performed using a combination of
different sequence read stringencies with the GSMapper software,
resulting in the generation of high confidence variant detection
(HCDiff) and a less conservative approach to detect all possible
sequence variants (AllDiff) (see Methods). Across all eight (related)
individuals that were sequenced with two full 454 runs, we
identified 21,533 unique variants, including SNPs and small
insertions and deletions (indels). Per individual we found 6790 –
11,038 loci heterozygous or homozygous for a variant allele based
on HCDiff; an average of 8744 (Table 2). Between 444 and 1163
variants per individual were not reported in dbSNP (v128) and
were thus categorized as putative novel alleles. On average 297
putative novel non-synonymous alleles were identified per
individual (Table 2). Individual 10036 yielded the most SNPs
and individual 10034 showed the least variants of all samples
(Table 2). As expected, this generally corresponds with the number
of mapped reads covering targeted regions in these samples, where
10036 had the most (4.0 M) and 10034 the least number of reads
(2.2 M) of all samples (Table 1). We note, however, that the
greatest benefits for SNP detection from adding additional read
data occurs as reads are increased in the range of 1 to
approximately 2.6 M reads, with more modest detection increases
observed as data is added beyond 2.6 M reads. We also searched
for variants that occurred +/2 2 bp from an exon boundary as
they have a high potential to interfere with exon/intron splicing
activity. We identified on average 54 such variants per individual
(Table S2). Individual 10039 was sequenced with two additional
GS FLX runs, yielding nearly twice the number of sequencing
reads and increased target coverage. In 10039 we identified 14,284
variants (88% known to dbSNP) with 624 of them being novel
non-synonymous SNPs (Table S3).
In order to take advantage of having sequenced related
individuals within a known pedigree structure, we also combined
raw sequencing read data from three siblings (10082, 10033,
10039) and analyzed them as a quasi single individual. As these
individuals share parental origin, we hoped to detect additional
variants above calling thresholds at regions of low coverage.
Indeed we were able to identify 17,498 variants based on HCDiff
in the combined dataset compared to 15,545 unique variants
in the original HCDiff files. Thus, the detection of an additional
11% of variants renders this approach an attractive strategy for
maximizing variant detection. A possible application would be the
combination of data from multiple affected individuals within a
single pedigree in order to maximize the probability of sampling a
risk-associated allele in the context of low overall sequence
coverage. In this case, even though the actual risk locus may
receive inadequate coverage within any given affected individual,
the pooling of reads at the locus across a group of such individuals
would greatly increase the probability of the mutant allele being
detected.
Sensitivity of Variant Identification
Ideally, error estimates for genotype calling should be based on
independently obtained and validated sequence data. In lieu of the
availability of known exome sequences for our eight individuals,
we genotyped all eight samples with the Illumina 1 M Duo
BeadChip, which contains ,1610
6 SNP markers. We applied a
number of stringent quality checks to all genotype calls derived
from these arrays to define a subset of high quality SNPs (see
Methods). Only genotypes that overlapped with targeted exons
were retained for further analysis. This resulted in 44,513 high
quality SNP loci for comparison to NGS data, which we used to
calculate sensitivity levels. Here, we define false negative as the
frequency at which individuals heterozygous or homozygous for
the variant alleles are incorrectly called as homozygous for the
reference allele. This relaxed definition of false negatives
recognizes that many exome capture studies will have genetic
variant discovery as a primary goal. When using the two different
outputs from GSMapper, ALLDiff and HCDiff, compared to the
Illumina BeadChip genotypes, a range is observed for the false
negative rates. Applying more inclusive AllDiff criteria, the false
Figure 2. Sequence coverage of targeted exons. The graph illustrates the cumulative coverage of targeted bases after sequencing 0.5 Gbp
(red), 1 Gbp (blue), 1.5 Gbp (green), and 2 Gbp (purple). 1 Gb resulted in nearly 10x coverage of 50% of all targets; 2 Gb of data increase this number
to 88%. Depending on a studies goal, maximum coverage might not always be required.
doi:10.1371/journal.pone.0008232.g002
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the very conservative HCDiff criteria a false negative rate of 21%
at 8x and 4% at 15x was calculated (Fig. 3). A potentially more
practical approach to calculating false negative rates is the
cumulative false negative rate, which considers all targets covered
at a given depth and higher. Under this assumption, targets
covered $8x were incorrectly called reference in 6.7% of all tested
SNPs for HCDiff and in 2% for ALLDiff.
Empirical Coverage-Based Variant Assessment
A significant parameter that must be determined when assigning
genotypes based on NGS data is the cut-off proportion of variant
allele reads for a genotype to be called heterozygous or
homozygous. Several end-user software packages (e.g. Lasergene,
CLC) allow for a static, but adjustable, cut-off threshold across all
covered nucleotide positions. More sophisticated strategies have
been developed, relying on maximum likelihood (e.g.,[26]) and
prior knowledge of allele frequencies ([27]), and these have
been implemented to target data from short-read sequencing
platforms. To empirically determine genotype-calling thresholds
on a coverage dependent basis we used Illumina genotype data to
optimize our genotype calling cut-offs (and thereby variant
detection). Rather than applying a rigid cut-off rate for
heterozygous variant reads across all loci (e.g. .30% variant
reads), the optimal calling threshold was defined as that frequency
which maximizes the number of correct NGS genotype calls
Table 2. Genomic variants detected in eight exomes based on 2 454 GS FLX runs of aligned data.
Individual 10032 10033 10034 10035 10036 10037 10039 10082 Avg. Range
KNOWN VARIANTS 7962 6342 6346 9480 9875 7924 9398 7165 8062 6342–9875
Non-Synonymous 3467 2687 2749 4059 4257 3363 3952 3108 3455 2687–4257
indel 49 38 34 69 73 41 65 56 53 34–73
SNP 3418 2649 2715 3990 4184 3322 3887 3052 3402 2649–4184
Synonymous 4495 3655 3597 5421 5618 4561 5446 4057 4606 3597–5618
indel 19 20 19 38 35 29 28 30 27 19–38
SNP 4476 3635 3578 5383 5583 4532 5418 4027 4579 3578–5583
NOVEL VARIANTS 607 456 444 844 1163 610 748 591 683 444–1163
Non-Synonymous 344 254 244 486 723 347 402 337 392 244–723
indel 49 44 31 118 296 48 58 115 95 31–296
SNP 295 210 213 368 427 299 344 222 297 210–427
Synonymous 263 202 200 358 440 263 346 254 291 200–440
indel 21 16 19 44 76 21 29 31 32 16–76
SNP 242 186 181 314 364 242 317 223 259 181–364
Total 8569 6798 6790 10324 11038 8534 10146 7756 8744 6790–11038
doi:10.1371/journal.pone.0008232.t002
Figure 3. Estimated error rates. Sensitivity of genotype calling based on HCDiff SNPs, AllDiff SNPs, and the proposed coverage-dependent
genotype calling approach. A) False negative rates are based on concordance with a subset of 44,513 SNPs that overlapped with genotypes obtained
with Illumina 1 M Duo BeadChips. The coverage-dependent variant calling approach that calibrates cut-off rates according to array-based genotypes
is the most sensitive method, detecting .96% of SNPs at 5x coverage and .99% of all SNPs at $8x coverage. B) False positive rates. HCDiff is the
most conservative algorithm, resulting in a smaller false positive rate, while the more relaxed dynamic genotype calling algorithm results in twice as
high error rates at lower coverage.
doi:10.1371/journal.pone.0008232.g003
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thresholds were determined for each discrete coverage depth (3x,
4x, etc) (Fig. 4). As described below, this empirically determined
variant calling approach improved the overall sensitivity to detect
variants compared to the standard HCDiff variant detection
algorithm, particularly at low coverage targets (Fig. 3A). Typical
cut-off values produced by our method were cl=12% and
cu=88% at lower coverage depth and increased to cl=22%
and cu=78% at coverage $15 (Fig. 4). Applying this approach,
we were able to identify at 5x coverage more than 96% of all
heterozygous and homozygous changes reported by the Illumina
1 M BeadChip (Fig. 3A). At 8x coverage 99.99% of SNPs were
identified (Fig. 3A). Although this approach allows us to maximize
sensitivity, the rate of erroneously reported variants (specificity) is
modestly increased at coverage depths of #10x (Fig. 3B).
The rationale for this genotype calling approach is derived from
the fact that errors may result from a combination of array-capture
methodology, sequencing technology, as well as from sampling
error at loci. There are a number of difficulties involved in
disentangling these factors. Normal variation in hybridization
conditions and sequencing runs will likely cause the relative
contribution of each of these sources of error to fluctuate between
individual samples and sequencing runs. Furthermore, aspects of
the sequenced population itself (e.g. heterozygosity levels) may also
influence the overall performance of genotype calling strategies.
The empirical optimization method proposed here allows all these
factors to be taken into account without having to independently
assess them. Given the fairly large and representative group of
SNPs evaluated, we expect that this basic approach for generating
cut-off values will generally be valid for other, unrelated samples,
but the exact values will likely prove contingent upon the specific
enrichment and sequencing technologies applied.
Specificity of Variant Identification
Here, we restrict our definition of false positives to the
appearance of an allele at a sequenced locus that is not present
in the Illumina dataset for the individual. This is a conservative
approach as it is likely over-estimating error; differences between
Illumina genotyping data and NGS data, when independently
assessed with capillary sequencing [28], are often resolved in favor
of NGS. We used 112,384 genotypes from the Illumina 1 M to
examine specificity across the targeted exome, regardless of
whether they were present in any of the eight individuals. Of
the three tested approaches, the HCDiff algorithm produced the
lowest false positive rate of 0.7% (Fig. 3B). ALLDiff resulted in an
only marginally higher false positive rate. As expected, the
empirical coverage-based genotype calling approach had de-
creased specificity at lower coverage; the average rate of artifactual
variant calls was 1.5% at targets covered with 3 to 11 reads. For
studies that are willing to accept this rate of specificity, it appears
to be worth considering a more aggressive genotype calling
approach at regions of low coverage. At sequence read coverage
.15x, the differences in error rates between the different variant
calling approaches become negligible.
As another measure of the incidence of false discovery, we also
attempted to confirm 53 randomly chosen HCDiff SNPs across
the exome by capillary sequencing. We found that all 53 SNPs
were correctly called as heterozygous and homozygous variants,
thereby verifying the low rate of incorrect genotypes obtained
from the HCDiff algorithm.
Mendelian Inheritance Checks
Finally, we calculated the total number of Mendelian inconsis-
tencies in the pedigree resulting from NGS genotype calls using
the HCDiff SNPs. These errors could either be attributed to
improper genotype assignment or to authentic de-novo events. As
summarized in Table S4, the Mendelian error is 0.5% at 10x and
0.2% at 15x. As expected, the frequency of Mendelian errors
diminishes as a function of increased sequence depth. This
indicates that a significant component of Mendelian inconsisten-
cies were genotyping errors attributable to sampling error resulting
from insufficient sequencing coverage. The contribution of de
novo events to Mendelian inconsistencies appears low, as we were
not able to confirm any de novo mutation in 47 suspected variants
(see below). Therefore, when lacking available genotyping data to
estimate sensitivity and specificity, Mendelian inconsistencies
derived from available pedigree structures can assist in gauging
overall levels of genotype error and could aid in the optimization
of genotype calling algorithms.
De-Novo Variation
We made use of the available pedigree to search for evidence of
de-novo changes. By filtering the entirety of detected variants
(Table 2) for novel variants that occurred in an offspring (10033),
but not in parents (10035 and 10036), we identified 47 changes
suggestive of de-novo mutation events. However, subsequent
capillary sequencing confirmed none of these variants as true de-
novo events. While this initially suggests a disturbingly high error
rate, it must be considered that by selecting alleles that appear to
be de novo mutants, we are also strongly biasing towards the set of
artifactual SNP calls in the offspring as well as those SNPs we
failed to detect in either parents. Both of these latter categories will
appear identical to de novo events in the pedigree data set. For
comparison, when loci were randomly selected for capillary
sequence validation, we observed dramatically lower levels of error
(see above). Nevertheless, the failure to authenticate any of the
putative de novo mutations does imply a relatively low de-novo
Figure 4. Variant read distribution across eight exomes.
Illustration of the dynamic nature of optimal cut-off rates for calling
heterozygous/homozygous variants. At lower coverage (,10x) the ideal
cut-off is 88% variant reads in our data, while it is 78% at coverage $20.
Optimal usage of data should take advantage even of low covered
targets. Data are based on comparison to Illumina genotyped SNPs.
Green triangles: Illumina heterozygous genotypes, Blue diamonds:
Illumina homozygous genotypes. NGS genotypes are placed according
to their percent variant reads (y axis).
doi:10.1371/journal.pone.0008232.g004
Targeted Exome Sequencing
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et al. [25], the de-novo mutation rate in the exome should be no
more than two variants per generation (1% of 175 de-novo
mutation events per generation genome-wide), and thus close to
the false positive error rate of the sequencing approach described
here (Fig. 3B). In addition, de novo mutations in coding exons
likely carry an increased risk for compromising organismal
viability, as compared to mutations elsewhere in the genome,
and hence they are less likely to be sampled among successful
births.
Conclusion
Genomic enrichment methods and NGS platforms are currently
undergoing rapid development, leading to leap frog advancements
in genomic discovery tools. The results described here can provide
only a snapshot in time of the possibilities and limitations of a
combined array-based hybridization and NGS strategy. Our data
indicate that exome scale array capture enrichment provides a
powerful tool for genomic targeting and variant detection in NGS
studies.
With the present approach we have achieved $8x coverage of
,90% of all targets with ,2 Gb of aligned sequence reads (Fig. 2).
Our coverage-dependent sensitivity rates suggest that between
80% and 99.99% of all variants (depending on what strategy is
used) will be correctly identified at this coverage level (Fig. 3). We
have detected up to 13,605 SNPs per individual based on the
conservative HCDiff algorithm (Table S3). Taking into account a
sensitivity of 84% with HCDiff (including all targets covered $3
reads) (Fig. 3A), we extrapolate a full set of 15,781 SNPs in
individual 10039; this is comparable to the SNP numbers recently
reported for six Caucasian exomes [29]. This also underlines,
however, that near complete variant detection requires extensive
sequence coverage in order to overcome variability in coverage
depth across target regions.
Since NGS performance is correlated to coverage depth, it is of
key interest for investigators to assess the ‘‘right’’ amount of
sequencing in order to maximize respective study goals within
budgetary constraints. Our data should provide empirical
guidelines for such decisions, which are likely to be generalizable
when using the same technologies (Figs. 2 and 3). Although the
safest strategy appears to be an average coverage $20x, a number
of targets will be covered with less sequencing reads in any study
due to enrichment uniformity issues with hybridization-based
approaches. For at least the next few years, studies involving
hundreds of individuals will find the expense of obtaining optimal
high coverage across all target loci a daunting prospect. Partly
to address such challenges, we have proposed an empirical
coverage-based genotype calling approach. Using this approach
we were able to greatly improve detection of variant alleles at 3x -
15x coverage (Fig. 3A). The ‘‘cost’’ of false positives (i.e. reduced
specificity), although more than twice that of conservative
algorithms, was below 1.5% and might be acceptable for rare
variant discovery studies (Fig. 3B). More conservative calling
approaches will be preferable for other study designs.
In summary, the human exome capture array combined with
GS FLX sequencing provides a powerful means to detect genomic
variation in .90% of all human exons. The results and models
presented here should aid future study designs aiming at detection
of exonic sequence variation.
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